NCT04327206 |
Live attenuated |
Determination of impact of BCG vaccination for reduction of COVID-19 severity in pandemic. |
Phase III |
Murdoch Childrens Research Institute |
https://clinicaltrials.gov/ct2/show/NCT04327206. |
NCT04328441 |
Live attenuated |
To investigate the influence of BCG vaccination on healthcare workers in order to get protection from COVID-19. |
Phase III |
UMC Utrecht |
https://clinicaltrials.gov/ct2/show/NCT04328441 |
NCT04352608 |
Inactivated |
To determine the safety and immunogenicity of trail inactivated COVID-19 vaccine in group of healthy peoples having age range of 18-59 years. |
Phase I/II |
Sinovac Research and Development Co., Ltd. |
Wanget al., 2020bWang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020b;14(1):64-68.
|
NCT04383574 |
Inactivated |
To assess safety as well as immunogenicity of inactivated COVID-19 vaccine |
Phase I/II |
Sinovac Research and Development Co., Ltd. |
Wanget al., 2020bWang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020b;14(1):64-68.
|
NCT04276896 |
Non-replicating Vector |
To study immunogenic response and safety concern of non-replicating vector COVID-19 vaccine. |
Phase I/II |
Shenzhen Geno-Immune Medical Institute |
https://clinicaltrials.gov/ct2/show/record/NCT04276896 |
NCT04313127 |
Vector base |
To develop Adenovirus Type 5 Vector base vaccine for study of safety, reacto-genesis and immune reactivity of COVID-19 vaccine. |
Phase I |
CanSino Biologics Inc. |
https://clinicaltrials.gov/ct2/show/record/NCT04313127 |
NCT04341389 |
Vector base |
To investigate the influence of Adenovirus Type 5 Vector base novel coronavirus vaccine in a group of healthy adults |
Phase II |
Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
https://clinicaltrials.gov/ct2/show/NCT04341389 |
NCT04324606 |
Non-replicating vector |
To investigate proficiency, safety and immunogenicity of COVID-19 vaccine in age group of 18-55 years. |
Phase I/II |
University of Oxford |
Folegatti et al., 2020Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.
|
ChiCTR2000031781 |
Vector base |
To investigate the influence of Adenovirus Type 5 Vector base novel coronavirus vaccine in a group of healthy adults having age range 18-60 years. |
Phase I/II |
Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
Smith et al., 2020Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat commun. 2020;11(1):1-3.
|
NCT04336410 |
Nucleic acid |
To investigate the nucleic acid vaccine against COVID-19. |
phase I |
Inovio Pharmaceuticals |
Smith et al., 2020Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat commun. 2020;11(1):1-3.
|
NCT04368728 |
Nucleic acid |
To study safety and immunogenicity and efficiency of RNA vaccine against COVID-19. |
phase I/II |
Biontech SE |
Mulligan et al., 2020Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature . 2020;586(7830):589-93.
|
ChiCTR2000032459 |
Inactivated vaccine |
Safety assessment and improve immunogenicity |
Phase I/II |
Beijing Institute of Biological Products, Sinopharm |
Gao et al., 2020Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
|
ChiCTR2000031809 |
Inactivated vaccine |
Safety and immunogenicity of inactivated COVID-19 vaccine |
Phase I/II |
Wuhan Institute of Biological Products, Sinopharm |
http://www.chictr.org.cn/showprojen.aspx?proj=52227 |
NCT04368988 |
Subunit vaccine |
Stable, pre-fusion S protein given with adjuvant, Matrix-M |
Phase I/II |
Novavax |
Wanget al., 2020cWang H, Yuntao Z, Baoying H, Wei D, Yaru Q, Wenling W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020c;182(3):713-721.
|
NCT04398147 |
Non-replicating viral vector vaccine |
Incorporates the adenovirus type 5 vector (Ad5-nCoV) |
Phase I/II |
CanSino Biological Incorporation, Beijing Institute of Biotechnology, Canadian Center for Vaccinology |
Wang et al., 2020cWang H, Yuntao Z, Baoying H, Wei D, Yaru Q, Wenling W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020c;182(3):713-721.
|
NCT04400838 |
Non-replicating viral vector vaccine |
Safety assessment and improve immunogenicity |
Phase I/II |
University of Oxford, AstraZeneca |
Wang et al., 2020cWang H, Yuntao Z, Baoying H, Wei D, Yaru Q, Wenling W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020c;182(3):713-721.
|
NCT04299724 |
Non-replicating viral vector vaccine |
Modified dendritic cells expressing SARS-CoV-2 minigenes |
Phase I/II |
Shenzhen Geno-Immune Medical Institute |
Badgujar, Badgujar, Badgujar, 2020Badgujar KC, Badgujar VC, Badgujar SB. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges. Diabetes Metab Syndr. 2020;14(5):1361-1376.
|
NCT04334980 |
DNA vaccine |
Spike oral DNA vaccine encoding S of SARS-CoV-2 |
Phase I |
Symvivo |
Badgujar, Badgujar, Badgujar, 2020Badgujar KC, Badgujar VC, Badgujar SB. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges. Diabetes Metab Syndr. 2020;14(5):1361-1376.
|
NCT04405076 |
RNA vaccine |
Stabilization of S protein mRNA vaccine |
Phase II |
Moderna |
Corbett et al., 2020Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al.SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567-71.
|